A Phase 4 interventional study of BG00012 (DMF) in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Completed at 37 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.
Sponsored by Biogen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis — 1 open to participants now, 1 under way, 1 of them phase 3. Dimethyl Fumarate · Multiple Sclerosis.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, this one is the 6th largest by enrollment, is one of 3 that started in 2013, is one of 10 in phase 4, and was the 7th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →1 of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis is open now. Recruiting first, the newest first:
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2013.
This study's enrollment of 237 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 86 across the 22 interventional studies. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
127 studies in Multiple Sclerosis by Biogen: 2 open now, 4 under way, 1 of them phase 3. Of 119 finished, 36 (30%) have results posted.
Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 28th largest by enrollment of the 79 interventional ones that give a count, is one of 11 that started in 2013, is one of 22 in phase 4, and was the 68th registered.
Biogen’s Multiple Sclerosis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 127 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal (GI)-related events reported by participants with relapsing forms of multiple sclerosis (MS) initiating therapy with dimethyl fumarate (DMF) in the clinical practice setting.
The secondary objectives of this study are as follows:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
Drug: BG00012 (DMF)
Also known as: Tecfidera, DMF, dimethyl fumarate
Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS)
Severity of GI-related events in DMF-treated participants using the MOGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
Time frame: 12 Weeks
Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale
Severity of GI-related events in DMF-treated participants using the MAGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
Time frame: 12 Weeks
Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy
Percentage of participants reporting GI symptoms on the MOGISS, by those who utilized symptomatic therapy.
Time frame: 12 Weeks
Duration of GI-related Episodes in DMF-treated Participants
In participants who took symptomatic therapy, the median duration of acute GI episodes (in hours) was summarized for the overall treatment period, by symptom (nausea, diarrhea, lower abdominal pain, upper abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence). Table only includes the symptom duration for those symptoms with start and stop times entered in the eDiary (evaluable GI episodes), based on the MAGISS.
Time frame: 12 Weeks
Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy
Percentage of participants reporting that they required GI symptomatic therapy, based on the MOGISS.
Time frame: 12 Weeks
Participants' Use of Symptomatic Therapy, by Type and Category
The symptomatic therapies used by DMF-treated participants were self-reported by type and category. Each participant may have taken more than one symptomatic therapy type but was counted only once within each therapy category. Acetylsalicylic acid (ASA) is abbreviated in the table.
Time frame: 12 Weeks
Summary of Use and Days on Symptomatic Therapy, by Category
The total duration (in days) of use of each symptomatic therapy by participants as a result of GI symptoms experienced by DMF-treated participants is presented. If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in the 'All Therapies' category.
Time frame: 12 Weeks
Number of DMF-treated Participants Who Discontinued DMF Due to GI-related Events Requiring Symptomatic Therapy
The last symptomatic therapy prior to last dose of study medication was used to summarize the number of participants who discontinued DMF due to GI-related events. Participants may have taken more than one symptomatic therapy but are counted only once in the 'All Therapies' category.
Time frame: 12 Weeks
| Milestone | Dimethyl Fumarate |
|---|---|
| Started | 237 |
| Safety population | 233 |
| Completed | 202 |
| Not completed | 35 |
| Withdrew: Did not receive any study drug | 4 |
| Withdrew: Adverse event | 24 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Physician decision | 3 |
Severity of GI-related events in DMF-treated participants using the MOGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
| units on a scale | Dimethyl Fumarate |
|---|---|
| Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS) | 4.8 ± 2.34 |
Severity of GI-related events in DMF-treated participants using the MAGISS to measure GI symptoms, based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
| units on a scale | Dimethyl Fumarate |
|---|---|
| Worst Severity Score of Overall GI Events, Modified Acute Gl Symptom Scale | 4.7 ± 2.13 |
Percentage of participants reporting GI symptoms on the MOGISS, by those who utilized symptomatic therapy.
| percentage of participants | Dimethyl Fumarate |
|---|---|
| Percentage of DMF-treated Participants Who Reported GI-related Symptoms and Who Utilized Symptomatic Therapy | 54.1 |
In participants who took symptomatic therapy, the median duration of acute GI episodes (in hours) was summarized for the overall treatment period, by symptom (nausea, diarrhea, lower abdominal pain, upper abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence). Table only includes the symptom duration for those symptoms with start and stop times entered in the eDiary (evaluable GI episodes), based on the MAGISS.
| hours | Dimethyl Fumarate |
|---|---|
| Nausea; n=88 | 2.0 ± 1.81 |
| Diarrhea; n=78 | 1.6 (0.0 to 11.0) |
| Lower Abdominal Pain; n=67 | 2.0 (0.0 to 8.0) |
| Upper Abdominal Pain; n=66 | 1.8 (0.1 to 9.5) |
| Vomiting; n=27 | 0.4 (0.0 to 8.0) |
| Indigestion; n=52 | 1.9 (0.0 to 11.0) |
| Constipation; n=7 | 6.0 (0.0 to 23.0) |
| Bloating; n=41 | 3.0 (0.0 to 12.7) |
| Flatulence; n=68 | 2.1 (0.2 to 12.7) |
Percentage of participants reporting that they required GI symptomatic therapy, based on the MOGISS.
| percentage of participants | Dimethyl Fumarate |
|---|---|
| Percentage of DMF-treated Participants Who Required GI Symptomatic Therapy | 54.1 |
The symptomatic therapies used by DMF-treated participants were self-reported by type and category. Each participant may have taken more than one symptomatic therapy type but was counted only once within each therapy category. Acetylsalicylic acid (ASA) is abbreviated in the table.
| participants | Dimethyl Fumarate |
|---|---|
| Category: Antacid | 57 |
| Therapy: Calcium carbonate | 50 |
| Therapy: Magnesium (Mg) hydroxide | 4 |
| Therapy: Aluminum (Al) hydroxide | 1 |
| Therapy: Al hydroxide, Mg hydroxide, simethicone | 3 |
| Therapy: ASA, citric acid, sodium bicarbonate | 2 |
| Therapy: Generic anatacid | 1 |
| Therapy: Nauzene | 1 |
| Therapy: Sucralfate | 1 |
| Category: Antisecretory/antimicrobial | 49 |
| Therapy: Bismuth subsalicylate | 49 |
| Category: Anti-acid production | 43 |
| Therapy: Omeprazole | 18 |
| Therapy: Ranitidine | 15 |
| Therapy: Famotidine | 14 |
| Therapy: Lansoprazole | 10 |
| Therapy: Pantoprazole | 3 |
| Therapy: Cimetidine | 1 |
| Category: Anti-bloating/anti-constipation agent | 33 |
| Therapy: Simethicone | 29 |
| Therapy: Docusate | 5 |
| Therapy: Alpha-galactosidase | 1 |
| Therapy: Enema | 1 |
| Category: Antidiarrheal (anti-peristaltic) | 32 |
| Therapy: Loperamide | 29 |
| Therapy: Diphenoxylate | 3 |
| Therapy: Dicyclomine | 2 |
| Category: Anti-emetic (central) | 18 |
| Therapy: Ondansetron | 8 |
| Therapy: Promethazine | 7 |
| Therapy: Dimenhydrinate | 3 |
| Therapy: Tetrahydrocannabinol | 1 |
| Category: Laxative, fiber/probiotic | 10 |
| Therapy: Generic laxative | 5 |
| Therapy: Psyllium fiber | 3 |
| Therapy: Culturelle | 2 |
| Category: Laxative, hygroscopic/osmotic | 10 |
| Therapy: Polyethylene glycol | 4 |
| Therapy: Phosphorated carbohydrate solution | 3 |
| Therapy: Sennosides | 2 |
| Therapy: Osmotic | 1 |
| Category: Laxative, prokinetic | 7 |
| Therapy: Bisacodyl | 7 |
| Category:Analgesic (nonsteroidal antiinflammatory) | 5 |
| Therapy: Ibuprofen | 3 |
| Therapy: Naproxen | 2 |
| Therapy: ASA | 1 |
| Category: Anti-allergic | 3 |
| Therapy: Montelukast | 2 |
| Therapy: Diphenhydramine | 1 |
| Category: Anti-emetic (pro-kinetic) | 3 |
| Therapy: Metoclopramide | 3 |
| Category: Analgesic | 2 |
| Therapy: Acetaminophen | 2 |
| Category: No treatment type recorded | 1 |
| Therapy: Not available | 1 |
The total duration (in days) of use of each symptomatic therapy by participants as a result of GI symptoms experienced by DMF-treated participants is presented. If a participant had multiple different therapies on the same day, the days on symptomatic therapy was calculated as 1 day in the 'All Therapies' category.
| days | Dimethyl Fumarate |
|---|---|
| All therapies; n=128 | 10.4 ± 13.46 |
| Antacid; n=57 | 5.9 ± 10.77 |
| Antisecretory/antimicrobial; n=49 | 6.3 ± 12.34 |
| Anti-acid production; n=43 | 9.0 ± 11.16 |
| Anti-bloating/anti-constipation agent; n=33 | 5.9 ± 10.86 |
| Anti-diarrheal (anti-peristaltic); n=32 | 3.9 ± 3.88 |
| Anti-emetic (central); n=18 | 2.9 ± 2.00 |
| Laxative, fiber/probiotic; n=10 | 5.0 ± 5.64 |
| Laxative, hygroscopic/osmotic; n=10 | 3.7 ± 3.06 |
| Laxative, prokinetic; n=7 | 1.6 ± 0.79 |
| Analgesic (nonsteroidal antiinflammatory); n=5 | 4.6 ± 7.50 |
| Anti-allergic; n=3 | 12.0 ± 9.85 |
| Anti-emetic; n=3 | 9.7 ± 12.42 |
| Analgesic; n=2 | 4.5 ± 4.95 |
| No treatment type recorded; n=1 | 1.0 ± NA |
The last symptomatic therapy prior to last dose of study medication was used to summarize the number of participants who discontinued DMF due to GI-related events. Participants may have taken more than one symptomatic therapy but are counted only once in the 'All Therapies' category.
| participants | Dimethyl Fumarate |
|---|---|
| All therapies | 13 |
| Anti-acid production | 10 |
| Antacid | 6 |
| Antisecretory/antimicrobial | 6 |
| Anti-diarrheal (anti-peristaltic) | 5 |
| Anti-emetic (central) | 5 |
| Anti-emetic (prokinetic) | 2 |
| Laxative, fiber/probiotic | 1 |
| Laxative, prokinetic | 1 |
Collected over All serious adverse events (SAEs) from time of signed/dated informed consent through 12 weeks of treatment plus 4 weeks (± 5 days) post last dose.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dimethyl Fumarate | — | 7/233 (3%) | 0/233 (0%) |
| Event | Dimethyl Fumarate |
|---|---|
| DiarrhoeaGastrointestinal disorders | 2/233 |
| Abdominal Pain LowerGastrointestinal disorders | 1/233 |
| Abdominal Pain UpperGastrointestinal disorders | 1/233 |
| NauseaGastrointestinal disorders | 1/233 |
| Salivary Gland CalculusGastrointestinal disorders | 1/233 |
| VomitingGastrointestinal disorders | 1/233 |
| LymphadenitisBlood and lymphatic system disorders | 1/233 |
| Atrial FibrillationCardiac disorders | 1/233 |
| Sudden Cardiac DeathGeneral disorders | 1/233 |
| Troponin IncreasedInvestigations | 1/233 |
Safety Population (participants who received at least 1 dose of DMF, recorded in diary data)
| Age, Continuous(years) | Dimethyl Fumarate |
|---|---|
| Mean | 46.9 ± 11.66 |
| Sex: Female, Male(Participants) | Dimethyl Fumarate |
|---|---|
| Female | 181 |
| Male | 52 |
The record gives a start of May 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate